Skip to main content

New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year

By: PRLog
PreventiveMedicineDaily.com Publishes Comprehensive Review on GLP-1 Medication Persistence Rates Despite Long-Term Treatment Recommendations

FRESNO, Calif. - Jan. 11, 2026 - PRLog -- PreventiveMedicineDaily.com has published a comprehensive analysis revealing that despite being designed for long-term use, most patients discontinue GLP-1 weight loss medications within the first year of treatment. The detailed review, supervised by Jose Rossello, MD, PhD, MCHM, examines real-world persistence data from 2024-2025 and highlights a significant gap between clinical recommendations and patient adherence patterns.

According to the comprehensive analysis published in "How Long Are People on Weight Loss Drugs?", only 40-63% of patients remain on GLP-1 medications at 12 months, with persistence rates dropping to approximately 15-25% at two years. The review examined multiple medications including semaglutide versus tirzepatide, and liraglutide (Saxenda), finding that once-weekly formulations demonstrate better persistence than daily injections. At the six-month mark, approximately 47% of patients remain on treatment, representing a critical period when many face challenges with side effects, cost, or insurance coverage changes.

"This disconnect between recommended long-term use and actual patient persistence raises important questions about treatment expectations, affordability, and support systems," according to the PreventiveMedicineDaily.com analysis. The review emphasizes that clinical guidelines recommend GLP-1 medications as chronic disease management tools with no maximum duration restrictions, yet real-world data consistently shows early discontinuation followed by significant weight regain in most patients.

The analysis identifies multiple factors contributing to early discontinuation, including medication costs averaging $900-$1,300 per month without insurance, gastrointestinal side effects, and widespread misperceptions of GLP-1 medications as short-term solutions. The review also highlights that newer medications like tirzepatide show improved persistence rates (55-73% at six months) compared to earlier GLP-1 formulations.

"Understanding real-world persistence patterns is essential for patients and healthcare providers to set realistic expectations and plan for long-term success," notes the PreventiveMedicineDaily.com editorial team. "Our goal is to provide evidence-based information that helps readers make informed decisions about preventive care and weight management strategies."

Related articles:

Natural GLP-1 Boosters

What Tea Is Best for Weight Loss

Caloric Needs Calculator (Interactive tool)


Contact
Jose Rossello (Owner)
Preventive Medicine Daily
***@preventivemedicinedaily.com

Photos: (Click photo to enlarge)

Weight Loss Medication Retention Rates


Source: Preventive Medicine Daily

Read Full Story - New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year | More news from this source

Press release distribution by PRLog

Recent Quotes

View More
Symbol Price Change (%)
AMZN  215.39
+3.65 (1.72%)
AAPL  253.78
+0.97 (0.38%)
AMD  196.06
-0.52 (-0.26%)
BAC  47.40
+0.34 (0.72%)
GOOG  309.37
+4.95 (1.63%)
META  622.42
-5.03 (-0.80%)
MSFT  398.87
-1.08 (-0.27%)
NVDA  182.58
-0.64 (-0.35%)
ORCL  153.84
-2.13 (-1.37%)
TSLA  398.75
+3.19 (0.81%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.